CN113508108B - 有机化合物的结晶和盐形式及其药物组合物 - Google Patents

有机化合物的结晶和盐形式及其药物组合物 Download PDF

Info

Publication number
CN113508108B
CN113508108B CN201980091991.XA CN201980091991A CN113508108B CN 113508108 B CN113508108 B CN 113508108B CN 201980091991 A CN201980091991 A CN 201980091991A CN 113508108 B CN113508108 B CN 113508108B
Authority
CN
China
Prior art keywords
salt
compound
tris
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980091991.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113508108A (zh
Inventor
S·阿尔塔夫
A·拉马克里希南
J·西泽莫尔
章世杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN113508108A publication Critical patent/CN113508108A/zh
Application granted granted Critical
Publication of CN113508108B publication Critical patent/CN113508108B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980091991.XA 2018-12-21 2019-12-20 有机化合物的结晶和盐形式及其药物组合物 Active CN113508108B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US62/784,083 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US62/791,571 2019-01-11
US201962882712P 2019-08-05 2019-08-05
US62/882,712 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
CN113508108A CN113508108A (zh) 2021-10-15
CN113508108B true CN113508108B (zh) 2024-12-24

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091991.XA Active CN113508108B (zh) 2018-12-21 2019-12-20 有机化合物的结晶和盐形式及其药物组合物

Country Status (22)

Country Link
US (2) US12297179B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898597A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022515239A (cg-RX-API-DMAC7.html)
KR (1) KR20220035022A (cg-RX-API-DMAC7.html)
CN (1) CN113508108B (cg-RX-API-DMAC7.html)
AU (1) AU2019403396B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012305A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001640A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009309A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210394A (cg-RX-API-DMAC7.html)
GE (2) GEP20247683B (cg-RX-API-DMAC7.html)
IL (1) IL284218B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210147A1 (cg-RX-API-DMAC7.html)
MA (1) MA54541A (cg-RX-API-DMAC7.html)
MX (1) MX2021007536A (cg-RX-API-DMAC7.html)
NI (1) NI202100055A (cg-RX-API-DMAC7.html)
PE (2) PE20260309A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551495A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106526UA (cg-RX-API-DMAC7.html)
TW (1) TWI875727B (cg-RX-API-DMAC7.html)
UA (1) UA130491C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020132471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622000A (en) * 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
MX2010010300A (es) 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Also Published As

Publication number Publication date
IL284218A (en) 2021-08-31
CO2021009309A2 (es) 2021-10-29
AU2019403396B2 (en) 2024-12-12
KR20220035022A (ko) 2022-03-21
NI202100055A (es) 2021-12-01
EP3898597A1 (en) 2021-10-27
JP2026001058A (ja) 2026-01-06
US20250270175A1 (en) 2025-08-28
GEP20247683B (en) 2024-10-28
GEAP202415700A (en) 2024-05-13
PE20212197A1 (es) 2021-11-16
UA130491C2 (uk) 2026-03-04
SG11202106526UA (en) 2021-07-29
JOP20210147A1 (ar) 2023-01-30
JP2022515239A (ja) 2022-02-17
MX2021007536A (es) 2021-09-23
MA54541A (fr) 2022-03-09
PH12021551495A1 (en) 2022-03-07
CA3124401A1 (en) 2020-06-25
JP7749080B2 (ja) 2025-10-03
CN113508108A (zh) 2021-10-15
US20220055995A1 (en) 2022-02-24
BR112021012305A2 (pt) 2021-10-05
CL2021001640A1 (es) 2022-06-03
WO2020132471A1 (en) 2020-06-25
IL284218B2 (en) 2026-05-01
WO2020132471A8 (en) 2020-08-06
US12297179B2 (en) 2025-05-13
PE20260309A1 (es) 2026-02-11
CR20210394A (es) 2021-12-13
TW202039448A (zh) 2020-11-01
IL284218B1 (en) 2026-01-01
JP2024161431A (ja) 2024-11-19
TWI875727B (zh) 2025-03-11
AU2019403396A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
JP7749080B2 (ja) 有機化合物の結晶および塩形態およびその医薬組成物
JP6737838B2 (ja) Mek阻害剤の調製およびmek阻害剤を含む製剤
CN101573350B (zh) 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼
CN115175904A (zh) Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CA3124401C (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
EA045339B1 (ru) Кристаллические и солевые формы органического соединения и их фармацевтические композиции
OA20637A (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof.
KR20230026384A (ko) 화합물의 결정 형태
WO2011027988A2 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
WO2024067085A1 (zh) 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途
HK1214254B (en) Preparation of and formulation comprising a mek inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant